National Marrow Donor Program

Petersdorf EW, KoIIman C, Hurley CK, Dupont B, Nademanee A, Begovich AB, Weisdorf D, McGIave P. Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia the US National Marrow Donor Program Experience. Blood. 2001 Nov 15 98(10) 2922-9. 

The majority of bone marrow transplant centers (especially those performing allogeneic bone marrow transplants) in the United States have a pharmacist on the team. Currently, there are approximately 450 bone marrow transplant centers registered in 48 different countries with the National Marrow Donor Program. In most cases, the pharmacist is employed by the Department of Pharmacy with partial or complete financial support from the Department of Medicine. With the stringent criteria... 

ITP idiopathic thrombocytopenic purpura MCSF macrophage colony-stimulating NMDP National Marrow Donor Program PBPC peripheral blood progenitor cell RBC red blood cell SCF stem cell factor TPO thrombopoietin WBC white blood cells... 

McGlave P, Shu XO, Wen W, et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia 9 years experience of the National Marrow Donor Program. Blood 2000 95 2219-2225. 

MHC major histocompatibility complex MLC mixed lymphocyte culture MLR mixed lymphocyte reaction MUD matched unrelated donor NMDP National Marrow Donor Program NMT nonmyeloablative transplant PBPC peripheral blood progenitor cell PBSC peripheral blood stem cell PCR polymerase chain reaction TBI total body irradiation UCB umbilical cord blood VOD (hepatic) veno-occlusive disease... 

Hurley CK, Lowe LB, Logan B, et al. National Marrow Donor Program HLA-matching guidelines for unrelated marrow transplants. Biol Blood Marrow Transplant 2003 9 610-615. 

Horowitz MM, Confer DL. Adverse events among 2408 unrelated donors of peripheral blood stem cells results of a prospective trial from the National Marrow Donor Program. Blood 2009 113 (15) 3604-11. 

---